Correction

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

Paul D Carey¹ , Bavanisha Vythilingum¹ , Soraya Seedat¹ , Jacqueline E Muller¹ , Michael van Ameringen² and Dan J Stein¹

¹MRC Research Unit on Anxiety Disorders, University of Stellenbosch, Cape Town, South Africa

²Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada

author email corresponding author email

BMC Psychiatry 2005, 5:44doi:10.1186/1471-244X-5-44

Published:	30 November 2005

First paragraph (this article has no abstract)

The comment in the introduction of our article [1] suggesting that "quetiapine is the only available antipsychotic with significant 5-HT1D effects," is misleading. The affinity of quetiapine for this receptor is low and probably insignificant when compared with some other second generation antipsychotics [2].